Teva posts strong rise in 2nd-qtr 2015 profits ahead of analysts' forecasts

31 July 2015

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) has reported a slight downturn in second-quarter 2015 sales, but significant profits growth. Teva’s shares dipped 2.4% to 26,460 Israeli shekels by close of Tel Aviv trading.

Teva, which has just announced a $40.5 billion acquisition of Allergan, said that revenues in the second-quarter amounted to $5.0 billion, down 2% compared to the like 2014 quarter, and beating analysts’ of $4.77 billion. Excluding the impact of foreign exchange fluctuations and the sale of the US over-the-counter (OTC) plants in July 2014, revenues grew 6%.

Non-generally-accepted accounting principles (GAAP) gross profit was $3.1 billion, up 7%. Non-GAAP growth profit margin was 62.8%, compared to 58.1% in the second quarter of 2014. GAAP gross profit was $2.9 billion in the second quarter of 2015, compared to $2.7 billion in the second quarter of 2014. GAAP gross profit margin was 58.4% in the quarter, compared to 52.7% in the second quarter of 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK